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Abstract: Our previous work has described a library of thioxanthones designed to have dual activity
as P-glycoprotein modulators and antitumor agents. Some of these compounds had shown a
significant cell growth inhibitory activity towards leukemia cell lines, without affecting the growth of
non-tumor human fibroblasts. However, their effect in cell lines derived from solid tumors has not
been previously studied. The present work aimed at: (i) screening this small series of compounds
from an in-house library, for their in vitro cell growth inhibitory activity in human tumor cell lines
derived from solid tumors; and (ii) initiate a study of the effect of the most potent compound on
apoptosis. The tumor cell growth inhibitory effect of 27 compounds was first analysed in different
human tumor cell lines, allowing the identification of a hit compound, TXA1. Its hydrochloride
salt TXA1¨HCl was then synthesized, to improve solubility and bioavailability. Both TXA1 and
TXA1¨HCl inhibited the growth of MCF-7, NCI-H460, A375-C5, HeLa, 786-O, Caki-2 and AGS cell
lines. The effect of TXA1¨HCl in MCF-7 cells was found to be irreversible and was associated, at
least in part, with an increase in cellular apoptosis.
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1. Introduction
Thioxanthones are isosteric analogues of xanthones, consisting of S-heterocycles with a
dibenzo-γ-thiopyrone scaffold. The first thioxanthone with promising therapeutic value, lucanthone
(Miracil D), appeared in the decade of the 1940s as an antischistossomal agent [1,2]. Several studies on
the biological activities of thioxanthones allowed their identification as anticancer agents, as well as
the identification of their mechanisms of action [2]. In addition, it was found that treatment with some
thioxanthones sensitized tumor cells to the effect of other chemotherapeutic agents, which enabled new
chemotherapeutic approaches [2]. Regarding the mechanism of action of thioxanthones, lucanthone
and its derivative hycanthone were found to be able to intercalate into DNA and to inhibit RNA
synthesis, as well as the DNA topoisomerases I and II [3]. Nevertheless, although presenting similarity
with other intercalating agents, their mutagenicity (mainly due to their methylene moiety directly
bound to C-4) discouraged their use in cancer chemotherapy [2,4]. Other examples of thioxanthones
with antitumor activity are SR233377 and SR271425 [5,6]. SR233377, a hycanthone derivative, is a
second-generation aminated thioxanthone which presented selectivity for mouse solid tumors when
compared to normal cells (using a disc diffusion in vitro assay) and was also confirmed to be active
in vivo in tumors implanted in murine models [5]. Nevertheless, it was found to be hepatotoxic.
This problem was latter overcome by the development of SR271425, a third-generation thioxanthone,
which presented a broad-spectrum activity against solid tumors both in vitro and in vivo (in murine
as well as in human xenograft tumor models) [6].
Although several thioxanthone derivatives have entered clinical trials as antitumor agents in the
last decade, their toxicity has largely limited their clinical utility [2,5–7]. In order to circumvent this
toxicity problem, which was associated with their pattern of substitution, and in order to improve
their efficiency, a small library of new thioxanthone derivatives with potential as antitumor agents and
simultaneously with P-glycoprotein (P-gp) inhibitory activity, was designed and recently obtained by
some of us [4]. These derivatives presented an oxygenated function in C-4, instead of the methylene
moiety associated with the toxicity exhibited by lucanthone. Even though some of these compounds
were previously shown to have both antitumor (and anti P-gp) activity in leukemia cell lines, while
not being toxic to non-tumor cells, their cell growth inhibitory activity in tumor cell lines derived from
solid tumors had not been previously studied.
Therefore, the main aim of the present study was to screen this small series of thioxanthones
regarding their cell growth inhibitory effect in a panel of human tumor cell lines derived from solid
tumors and, in addition, to gain some insights into the mechanism of action of TXA1¨HCl, the
hydrosoluble hydrochloride derivative of the most potent compound, 1-{[2- (diethylamino)ethyl]-
amino-4-propoxy-9H-thioxanthen-9-one (TXA1), in MCF-7 breast cancer cells.
2. Results and Discussion
2.1. Screening of a Small Library of Xanthones for Their Cell Growth Inhibitory Activity in Human Tumor Cell
Lines Derived from Solid Tumors: Identification of TXA1 as a Hit Compound
Previous studies carried out by some of us had shown that a library of thioxanthones 1–27 (Table 1)
presented potent cell growth inhibitory effect in leukemia cell lines. In addition, these compounds had
also been tested in MRC5 non-tumor human cells, and had previously been shown not to affect their
growth [4]. In the present work, the in vitro cell growth inhibitory effect of this series of compounds
was screened in three human tumor cell lines representative of solid tumors. For that, the GI50
concentrations were determined for the 27 thioxanthones in MCF-7 (breast adenocarcinoma), NCI-H460
(non-small cell lung cancer, NSCLC) and A375-C5 (melanoma) cells, using the sulforhodamine B assay
Molecules 2016, 21, 81 3 of 16
which allows to indirectly assess cell number by measuring the amount of proteins in cells following
treatment [8] (Table 1).
Table 1. GI50 values determined for the 27 thioxanthones following continuous treatment of the three
human tumor cells lines during 48 h.
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Table 1. Cont.
Thioxanthone
Number
R
GI50 (µM)
MCF-7 NCI-H460 A375-C5
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Thioxanthone 
Number R 
GI50 (µM) 
MCF-7 NCI-H460 A375-C5
13 >150 >150 >150 
14 34.0 ± 3.1 39.3 ± 6.4 24.3 ± 3.3 
15 65.7 ± 1.5 59.3 ± 7.9 55.0 ± 1.5 
16 28.3 ± 2.9 22.7 ± 2.5 20.0 ± 2.1 
17 >150 >150 >150 
18 >150 >150 >150 
19 70.8 ± 6.9 61.3 ± 4.1 54.8 ± 9.4 
20 34.3 ± 3.0 35.0 ± 5.2 34.0 ± 4.0 
21 >150 >150 >150 
22 R = OCH3, R’ = OH >150 >150 >150 
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25 R = Cl, R’ = OAc 9.4 ± 0.2 8.7 ± 0.2 8.2 ± 0.3 
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not shown). Doxorubicin was used as a positive control (GI50 concentrations: 65 ± 8.5 nM in MCF-7, 
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64 ± 6.8 nM in NCI-H460 and 145 ± 9.8 nM in A375-C5 cells). 
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vehicle (DMSO) c ncentration s  was 0.25% and was shown not to interfere with cell growth (data 
not shown). Doxorubicin was used as a positive control (GI50 concentrations: 65 ± 8.5 nM in MCF-7, 
64 ± 6.8 nM in NCI-H460 and 145 ± 9.8 nM in A375-C5 cells). 
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26 
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27 R = H, R’ = OH 39.0 ± 3.6 28.7 ± 2.2 34.0 ± 6.5 
The values presented refer to the mean ± SEM of at l ast three independent experiments. The maximum 
vehicle (DMSO) concentration used was 0.25% and was shown not to interfere with cell growth (data 
not shown). Doxorubicin was used as a positive control (GI50 concentrations: 65 ± 8.5 nM in MCF-7, 
64 ± 6.8 nM in NCI-H460 and 145 ± 9.8 nM in A375-C5 cells). 
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NCI-H460 and 145 ˘ 9.8 nM in A375-C5 cells).
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Results obtained 48 h after continuous treatment showed that, from all the studied thioxanthones,
two compounds, 1 and 25, were found to be the most potent on the studied cell lines (presenting GI50
concentration lower than 10 µM). By comparing the GI50 concentration of the compounds in the studied
tumor cell lines (derived from solid tumors) with our previous published work on the chronic myeloid
leukemia cell line (K562) [4], compound 25 was found to be a more potent growth inhibitory agent
towards the solid tumor cell lines (MCF-7, NCI-H460 and A375-C5) than towards the K562 chronic
myeloid leukemia cell line (previously determined GI50 = 13.57 ˘ 2.96 µM) [4]. On the other hand,
compounds 4, 12, 14, 23 and 26 presented much higher GI50 concentrations in the cell lines studied in
the present study, when compared with the previously GI50 concentrations determined in K562 cells
(3.73 ˘ 1.47 µM, 4.81 ˘ 4.21 µM, 3.00 ˘ 0.48 µM, 4.47 ˘ 1.93 µM, 4.38 ˘ 0.44 µM, respectively) [4].
The most potent compound 1, herein designated as the hit compound TXA1, was selected to be
further studied in order to investigate its cellular mechanism(s) of action. In a previous study, the
compound had been found to be non-toxic to non-tumor cells [4]. Interestingly, the amine side chain of
compound 1 was structurally very similar to lucanthone, the first thioxanthone described as a potential
antitumor agent (originally used as an anti-schistosomal drug) which has already reached clinical
trials [2,3].
2.2. Synthesis of TXA1¨HCl
Before proceeding with the study of the mechanism of action and in order to improve the solubility
and bioavailability characteristic of TXA1, its hydrochloride salt (TXA1¨HCl) was synthesized.
As previously published, TXA1 had been obtained with a 30% yield by an aromatic nucleophilic
substitution reaction under copper catalysis [4]. Herein, using a multimilligram approach in a basic
media (K2CO3) in closed vessel, followed by the neutralization reaction of the organic free amine with
hydrochloric acid, TXA1¨HCl was obtained in a 50% overall yield (Scheme 1). This procedure, besides
being successful in the formation of the hydrochloride salt of TXA1, also allowed its purification
without applying chromatographic methodologies.
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(GI50 = 9.7 µM) was nearly four times more potent than TXA1 (GI50 = 35.3 µM). 
To further confirm the cytotoxic effect of TXA1 and TXA1·HCl in these cells, another assay, the 
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the IC50 concentrations (50% inhibitory concentration) determined with the MTT assay for TXA1  
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Scheme 1. Synthesis of TXA1 and its hydrochloride salt, TXA1¨HCl.
2.3. TXA1 and TXA1¨HCl Inhibit Cell Growth of a Larger Panel of Human Tumor Cell Lines Derived from
Solid Tumors
The effect of TXA1¨HCl was then analyzed in a larger panel of human tumor cell lines, in parallel
with TXA1. Determination of the GI50 concentration of both TXA1 and TXA1¨HCl in this larger
panel (which also included the previously studied cell lines, see Table 1), allowed to conclude that
the hydrochloride form of the compound (TXA1¨HCl) presented similar activity to the non-soluble
TXA1 form (Table 2). The major difference observed was in the AGS gastric cancer cell line, in which
TXA1¨HCl (GI50 = 9.7 µM) was nearly four times more potent than TXA1 (GI50 = 35.3 µM).
To further confirm the cytotoxic effect of TXA1 and TXA1¨HCl in these cells, another assay, the
MTT assay which measures metabolic activity, was carried out in four of the studied cell lines (A375-C5,
MCF-7, NCI-H460 an HeLa).
As expected, a dose-dependent decr ase in metabolic activity occurred in all of the studied cell
lines following continu us c llular treatment w th TXA1 or TXA1¨HCl (Figure 1). These results were
in agreement with the dose-response curves obtained with he SRB assay (data not shown). Moreover,
Molecules 2016, 21, 81 6 of 16
the IC50 concentrations (50% inhibitory concentration) determined with the MTT assay for TXA1
(5.92 ˘ 0.51 µM in A375-C5, 8.24 ˘ 0.16 µM in MCF-7, 7.88 ˘ 0.27 µM in NCI-H460 and 7.10 ˘ 0.06 µM
in HeLa) and for TXA1¨HCl (4.53 ˘ 0.24 µM in A375-C5, 8.64 ˘ 0.42 µM in MCF-7, 9.79 ˘ 0.50 µM
in NCI-H460 and 6.42 ˘ 0.33 µM in HeLa) were within the same range of the GI50 concentrations
previously determined with the SRB assay (Table 2).
Table 2. GI50 values determined for the TXA1 and TXA1¨HCl in various tumor cell lines derived from
solid tumors.
Compound GI50 (µM)
MCF-7 NCI-H460 A375-C5 HeLa 786-O Caki-2 AGS
TXA1 6.1 ˘ 0.4 # 6.0 ˘ 0.3 # 3.6 ˘ 1.2 # 6.8 ˘ 0.5 8.1 ˘ 1.8 11.5 ˘ 1.8 35.3 ˘ 2.3
TXA1¨HCl 7.8 ˘ 0.9 6.9 ˘ 1.3 3.8 ˘ 0.8 6.4 ˘ 0.6 9.0 ˘ 1.1 9.3 ˘ 0.8 9.7 ˘ 0.2
Values presented refer to the mean ˘ SEM of at least three independent experiments. The maximum vehicles
(DMSO for TXA1 and H2O for TXA1¨HCl) concentration used was 0.25% and did not interfere with cell growth
(data not shown). Doxorubicin was used as a positive control [GI50 concentrations: 65 ˘ 8.5 nM in MCF-7,
64 ˘ 6.8 nM in NCI-H460, 145 ˘ 9.8 nM in A375-C5, 20.7 ˘ 0.8 nM in HeLa, 135 ˘ 6.2 nM in 786-O, 152.3
nM in Caki-2 (from two experiments only), 90 ˘ 5 nM in AGS]. # data also included in Table 1 as the GI50
concentration of compound 1.
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2.4. The Effect of TXA1·HCl in MCF-7 Cells is Irreversible 
In order to investigate if the cytotoxic effects of TXA1·HCl were irreversible, MCF-7 cells were 
treated with increasing concentrations of this compound for 6, 12, 24 or 48 h, after which the compound 
was removed and cells left to recover in fresh medium for an additional 24 or 48 h. The reason to 
include the 6 h treatment was that preliminary experiments showed that a 10 h incubation period with 
the compound was enough to induce morphology changes in MCF-7 cells (data not shown). Following 
the recovery period, the MTT assay was performed and corresponding dose-response curves were 
generated (Figure 2). Results showed that the effect of TXA1·HCl was both time- and dose-dependent. 
Although no changes were observed in the cellular metabolic activity (measured with MTT assay) 
following 6 h of treatment with TXA1·HCl, a significant decrease in metabolic activity was observed 
in these cells upon 48 h of recovery. This seems to indicate that 6 h treatment with TXA1·HCl is 
sufficient to interfere with the mechanisms involved in cell survival and proliferation, even though this 
effect can only be observed latter. In addition, TXA1·HCl treatment for 12 h resulted in a pronounced 
decrease in cellular metabolic activity (when comparing with the 6 h exposure). Moreover, no recovery 
was observed upon the 24 or the 48 h recovery period, when an even higher decrease in the cellular 
metabolic activity was observed. The same trend was observed in cells initially treated for 24 or 48 h 
Figure 1. Effect of TXA1 (a) and TXA1¨HCl (b) in four human tumor cell lines, analyzed with the
MTT assay. Cells (A375-C5, MCF-7, NCI-H460 and HeLa) were continuously treated with TXA1 or
TXA1¨HCl for 48 h. Metabolic activity is expressed as percentage of blank (cells treated with medium
only). Results are expressed as mean ˘ SEM of at least three independent experiments. The maximum
vehicle (DMSO for TXA1 and H2O for TXA1¨HCl) concentration was used as control and did not
interfere with the cellular metabolic activity (data not shown).
2.4. The Effect of TXA1¨HCl in MCF-7 Cells is Irreversible
In order to investi ate if the cytot xic effects f TXA1¨HCl were irreversible, MCF-7 cells were
treated with increasing concentrations of this compound for 6, 12, 24 or 48 h, after which the compound
was removed and cells left to recover in fresh medium for an a ditional 24 or 48 h. The reason to
include the 6 h treatment was that pr liminary experiments showed that a 10 h incubation period with
the comp und was enough to induce morphology changes in MCF-7 cells (data not shown). Following
the recovery period, the MTT assay was performed and corresponding dose-response curves were
generated (Figure 2). Results showed that the effect of TXA1¨HCl was both time- and dose-dependent.
Although no changes were observed in the cellular metabolic activity (measured with MTT assay)
following 6 h of treatment with TXA1¨HCl, a significant decrease in metabolic activity was observed
in these cells upon 48 h of recovery. This seems to indicate that 6 h treatment with TXA1¨HCl is
sufficient to interfere with the mechanisms involved in cell survival and proliferation, even though this
effect can only be observed latter. In addition, TXA1¨HCl treatment for 12 h resulted in a pronounced
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decrease in cellular metabolic activity (when comparing with the 6 h exposure). Moreover, no recovery
was observed upon the 24 or the 48 h recovery period, when an even higher decrease in the cellular
metabolic activity was observed. The same trend was observed in cells initially treated for 24 or 48 h
with TXA1¨HCl, although the reduction in cellular metabolic activity was increasingly higher in these
situations. These results indicate that the TXA1¨HCl effect on MCF-7 cells is irreversible.
Molecules 2016, 21, 81 7 of 15 
 
with TXA1·HCl, although the reduction i   tabolic activity was increasingly higher in these 
situations. Th se results indicate that the TX · l effect on MCF-7 cells is irreversible. 
 
Figure 2. Analysis of the reversibility of the effect of TXA1·HCl in MCF-7 cells, analyzed with the 
MTT assay. Cells were treated with increasing concentrations of TXA1·HCl for 6 h (a); 12 h (b); 24 h 
(c) or 48 h (d) and then incubated for an additional 24 or 48 h in compound-free medium. Metabolic 
activity is expressed as percentage of blank (cells treated with medium only). Results are expressed 
as mean ± SEM from three independent experiments. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001 
when comparing treatment vs. control (H2O). 
In order to confirm the irreversibility effect of TXA1·HCl, the colony forming (or clonogenic) assay 
was carried out in the MCF-7 cells. For this, cells were treated with 5, 10 and 20 µM TXA1·HCl for  
6 and 24 h, after which the compound was removed and the cells allowed to recover for 14 days. The 
number of colonies formed was then determined (Figure 3). 
As expected, TXA1·HCl caused a time- and concentration-dependent decrease in the colony-forming 
capability of MCF-7 cells. Treatment with 20 µM TXA1·HCl for 6 h only resulted in a significant 
reduction of approximately 70% in the number of colonies when compared with the treatment with 
solvent control. The reduction was even more evident when the cells were treated for 24 h with the 
same concentration (20 µM), with no colonies having been observed. In addition, 24 h treatment with 
lower concentrations (5 and 10 µM) significantly decreased the colony forming capability of cells 
approximately by 30% and 95%, respectively. 
Naturally-occurring xanthones have shown similar effects in tumor cells. For example,  
α-mangostin, a prenylated xanthone isolated from the mangosteen fruit, inhibited colony formation 
in prostate cancer cells [9]. Also, the caged xanthone gambogic acid significantly inhibited the colony 
formation capability of glioblastoma cells [10]. 
Overall, the results obtained from the MTT assay and from the colony forming assay demonstrate 
that, as for other xanthones, TXA1·HCl may act as a cytotoxic, rather than as a cytostatic compound, 
with its effect being irreversible following at least 6 h exposure. Therefore, this compound is possibly 
an inducer of cell death. 
Figure 2. Analysis of the reversibility of the effect of TXA1¨HCl in MCF-7 cells, analyzed with the
MTT assay. Cells were treated with increasing concentrations of TXA1¨HCl for 6 h (a); 12 h (b); 24 h
(c) or 48 h (d) and then incubated for an additional 24 or 48 h in compound-free medium. Metabolic
activity is expressed as percentage of blank (cells treated with medium only). Results are expressed as
mean ˘ SEM from three independent experiments. * p ď 0.05; ** p ď 0.01; *** p ď 0.001; **** p ď 0.0001
when comparing treatment vs. control (H2O).
In o d r t co firm the irreversibili y eff ct of TXA1¨HCl, the colony forming (or clonogenic)
assay was carried out in MCF-7 cells. For this, cells wer treated ith 5, 10 and 20 µM TXA1¨HCl
for 6 and 24 h, after which the compound was removed and the cells allowed to recover for 14 days.
The numb r of colonies formed was then determin d (Figure 3).
As expected, TXA1¨HCl caused a time- and concentration-dependent decrease in the
colony-forming capability of MCF-7 cells. Treatment with 20 µM TXA1¨HCl for 6 h only resulted
in a significant reduction of approximately 70% in the number of colonies when compared with the
treatment with solvent control. The reduction was even more evident when the cells were treated
for 24 h with the same concentration (20 µM), with no colonies having been observed. In addition,
24 h treatment with lower concentrations (5 and 10 µM) significantly decreased the colony forming
capability of cells approximately by 30% and 95%, respectively.
Naturally-occurring xanthones have shown similar effects in tumor cells. For example,
α-mangostin, a prenylated xanthone isolated from the mangosteen fruit, inhibited colony formation in
prostate cancer cells [9]. Also, the caged xanthone gambogic acid significantly inhibited the colony
formation capability of glioblastoma cells [10].
Overall, the results obtained from the MTT assay and from the colony forming assay demonstrate
that, as for other xanthones, TXA1¨HCl may act as a cytotoxic, rather than as a cytostatic compound,
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with its effect being irreversible following at least 6 h exposure. Therefore, this compound is possibly
an inducer of cell death.Molecules 2016, 21, 81 8 of 15 
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Several st ies have shown that one of the main mechanisms involved in the antitumor effect of
xanthones is the induction of cell death by apoptosis. For example, γ-mangosti was shown to induce
apoptosis in human colon cancer cells [11]. In addition, α-mangostin induce cell cycle arrest and
apoptosis in breast cancer [12] and in prostate cancer [9] cells. Also, gambogic acid induced cell cycle
arrest and apoptosis in glioblastoma cells [10]. Pyranocycloartobiloxanthone A, a xanthone isolated
from Artocarpus obtusus, ind ced apoptosis in MCF-7 cells [13] and a xanthone isolated from Garcinia
oblongifolia induced apoptosis in hepatocellular carcinoma cells [14].
Preli inary experi ents, in hich PI-stained of 1¨ l treated cells as observed
by fl orescence icroscopy, sho e the presence of bright I-staine icron clei, s ggestive of
cell eath by apoptosis ( ata not sho n).
Therefore, the effects of TXA1¨HCl in MCF-7 cellular morphology was further studied. A time
and dose-dependent effect on cellular morphology was clearly observed (Figure 4), such as cell
shrinkage, detachment and membrane blebbing, which were suggestive of apoptosis [15]. These
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morphological alterations were observed with the 10 µM and higher TXA1¨HCl concentrations.
The same was observed in HeLa cells following treatment with this compound (Supplementary Figure S1).
Furthermore, regular monitoring of the cells revealed that these effects were already evident following
10–12 h treatment (data not shown). To further confirm the effect of TXA1¨HCl on cell death, the
TUNEL assay was carried out.Molecules 2016, 21, 81 9 of 15 
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(nearly all cells were dead). 
To further confirm that apoptosis was the cause of this cell death, flow cytometry analysis following 
Annexin V-FITC and propidium iodide (PI) staining was carried out. This is a specific apoptosis assay 
(detecting both early and late stage apoptosis) and also more sensitive that the TUNEL assay [16,17]. 
Results (Table 3) indicated that 48 h treatment with 5 µM TXA1·HCl did not induce apoptosis, in 
agreement with the above TUNEL assay results. However, treatment with 10 µM TXA1·HCl induced 
apoptosis in approximately 50% of the cells analyzed. This percentage of apoptosis was very high when 
compared to that of TUNEL-positive cells determined for the same concentration and at the same 
time-point (1.8% ± 0.8%). Nevertheless, as previously mentioned, this is because the Annexin-V 
FITC/PI analysis is much more sensitive than the TUNEL assay, allowing to detect apoptosis at earlier 
stages (early apoptosis) whereas the TUNEL assay only detects cells with breaks on the DNA (late 
apoptosis) [18]. 
Figure 4. Effect of TXA1¨HCl treatment in MCF-7 cells, analyzed by phase contrast microscopy. Cells
were treated for 14, 24, 48 and 72 h with medium only (Blank), H2O and TXA1¨HCl (5, 10 and 20 µM).
Images are representative of at least three independent experiments. Scale bar = 40 µm.
Results showed a time- and dose-dependent increase in the percentage of TUNEL-positive cells
(Figur 5), sugges ive of increased apoptosis. Whil no induc ion of cell dea was observed with
the lower concentration of TXA1¨HCl (5 µM) at the earlier time points (24 and 48 h), the highest
tre tment conc ntration (20 µM) resulted in increased levels of TUNEL-positive cells at th se time
points. When an lyzing the effect of a longer period of treatment (72 h), a clear and significant increase
in the percentage of cell death was observed following treatment with 5 µM (8.8% ˘ 1.9%), 10 µM
(22.1% ˘ 3.4%) or 20 µM (nearly all cells were dead).
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Figure 5. Effect of TXA1¨HCl treatment in MCF-7cell death, analyzed with the TUNEL assay. Cells
were treated for 24, 48 and 72 h with medium only (Blank), H2O and TXA1¨HCl (5, 10 and 20 µM).
(a) Representative fluorescence microscopy images showing increasing TUNEL-positive cells (green)
as induced by 5, 10 or 20 µM of TXA1¨HCl, while fe or no TUNEL-positive cells were observed in
control cultur s (Blank and H2O). DNA was st ined with DAPI (blue); bar = 40 µm; (b) Quantification
of the levels of cell death. Results are the mean ˘ SEM from at least three independent experiments.
* p ď 0.05; ** p ď 0.01; *** p ď 0.001; **** p ď 0.0001 when comparing treatment vs. control (H2O).
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To further confirm that apoptosis was the cause of this cell death, flow cytometry analysis
following Annexin V-FITC and propidium iodide (PI) staining was carried out. This is a specific
apoptosis assay (detecting both early and late stage apoptosis) and also more sensitive that the
TUNEL assay [16,17]. Results (Table 3) indicated that 48 h treatment with 5 µM TXA1¨HCl did not
induce apoptosis, in agreement with the above TUNEL assay results. However, treatment with 10 µM
TXA1¨HCl induced apoptosis in approximately 50% of the cells analyzed. This percentage of apoptosis
was very high when compared to that of TUNEL-positive cells determined for the same concentration
and at the same time-point (1.8% ˘ 0.8%). Nevertheless, as previously mentioned, this is because
the Annexin-V FITC/PI analysis is much more sensitive than the TUNEL assay, allowing to detect
apoptosis at earlier stages (early apoptosis) whereas the TUNEL assay only detects cells with breaks
on the DNA (late apoptosis) [18].
Table 3. Levels of apoptosis in MCF-7 cells following treatment with TXA1¨HCl.
Treatment Apoptotic Cells (%)
Blank 11.0 ˘ 0.6
H2O 10.1 ˘ 1.4
TXA1¨HCl 5 µM 13.7 ˘ 0.410 µM 51.5 ˘ 5.0 *
Cells were treated for 48 h with medium (Blank), H2O or with TXA1¨HCl (5 µM or 10 µM). Results refer to the
values determined by flow cytometry analysis following Annexin V-FITC/PI staining and are the mean ˘ SEM
of at least three independent experiments. * p ď 0.05 when comparing treatment vs. control (H2O).
This further supports the results previously obtained, in which only the higher concentrations of
TXA1¨HCl (or prolonged drug treatment) induced cell death.
3. Experimental Section
3.1. General Information
Purification of compounds was performed by flash chromatography using silica gel 60
(0.040–0.063 mm, Merck, Darmstadt, Germany) and chromatography flash cartridges (GraceResolv,
Grace Company, Deerfield, IL, USA). Thin layer chromatography (TLC) using Merck silica gel 60
(GF254) was used for monitoring reactions and as purity criteria. The reactions were considered
finished, when one of the reagents was no longer detectable by TLC or remained constant over 30 min.
The purity of TXA1¨HCl was >95% determined by HPLC-DAD analysis using an isocratic elution
of MeOH:H2O 8:2 nade alkaline with TEA (1%) at a constant flow rate of 1.0 mL¨min´1 [4]. Melting
points were obtained in a Köfler microscope. IR spectra were measured on an Mattson Genesis
series FTIR (ATI, Unicam Sistemas analíticos, Linda-a-Velha, Portugal; software: WinFirst v.2.10)
spectrophotometer in KBr microplates (cm´1). 1H spectra were taken in DMSO-d6 DRX-500
(500.13 MHz for 1H) spectrometer (Bruker, Biosciences Corporation, Billerica, MA, USA). Chemical
shifts are expressed in δH (ppm) values relative to Me4Si as an internal reference. TX and A1 were
obtained from Sigma-Aldrich (Steinhein, Germany) and were of pro analysis grade.
3.2. Compound Synthesis
Synthesis of compounds 1–27 was performed according to the described procedure [4]. The purity
of each compound was determined by HPLC–DAD analysis using an isocratic elution of MeOH:H2O
basified with TEA (1%) or acidified with CH3COOH (1%) at a constant flow rate of 1.0 mL/min [4].
All tested compounds possessed a purity of at least 95%. Compounds were dissolved in DMSO.
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3.3. Multimilligram Synthesis of TXA1
Four individual mixtures of TX (500 mg; 2.0 mmol), amine A1 (0.44 mL, 4.0 mmol), K2CO3
(442 mg; 4.0 mmol), Cu2O (2 mg) and MeOH (20 mL) were placed in closed vessels. The mixtures
were allowed to react in parallel at 100 ˝C, with no stirring, during 24 h. The reaction mixtures
were recombined, filtered and concentrated under reduced pressure furnishing a dark brown crude
product. The crude product was dissolved with diethyl ether (30 mL), made alkaline with an aqueous
solution of NaOH 20% and washed with water (3 ˆ 30 mL). The ether fraction was dried (Na2SO4),
filtered and concentrated under vacuum. This concentrate was used to the next reaction without
further purification.
3.4. Synthesis of TXA1 Hydrochloride (TXA1¨HCl)
The ether solution obtained in the previous section was cooled at ´4 ˝C and a concentrated
hydrochloric solution 37% (1 mL) was added. An orange precipitate was formed and it was placed
at ´4 ˝C overnight. The solid thus obtained was filtered, washed with 90 mL of diethyl ether, and
dried in a desiccators containing phosphorus pentoxide furnishing a dark orange solid corresponding
to TXA1¨HCl (1.39 g, 51%). m.p. >48 ˝C dec; IR (KBr) υmax: 3425; 2960; 2930; 2874; 2655; 1614; 1573;
1508 cm´1; 1H-NMR (DMSO-d6, 500.13 MHz) δH: 7.52 (1H, s), 6.71 (1H, s), 6.61 (1H, s), 6.33 (1H, s),
6.32 (1H, s), 5.90 (1H, s), 3.19 (4H, m), 3.03 (6H, m), 1.19 (2H, m), 1.07 (6H, t, J = 7.1), 0.56 (3H, t, J = 7.1).
3.5. Cell Culture
A375-C5 (malignant melanoma), MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell
lung cancer), 786-O (renal cell adenocarcinoma) and AGS (gastric adenocarcinoma) cell lines were
cultured in RPMI-1640 medium with UltraGlutamine I and 25 mM Hepes (Lonza, Basel, Switzerland)
supplemented with 5% Fetal bovine serum (FBS, Biowest, Nuaillé, France). Caki-2 (clear cell carcinoma)
cells were cultured in McCoy’s 5A (Life Technologies, Carlsbad, CA, USA) supplemented with 10%
(v/v) FBS. HeLa (cervical adenocarcinoma) cells were cultured in DMEM (PAA Laboratories, Pasching,
Austria) supplemented with 10% (v/v) FBS. All cell lines were grown in monolayer cultures and kept
permanently in exponential growth in a humidified incubator, at 37 ˝C and a 5% CO2 atmosphere.
Cell number and viability were assessed with Trypan blue exclusion assay.
3.6. In Vitro Screening for Tumor Cell Growth Inhibition with the Sulforhodamine B Assay
The sulforhodamine B (SRB) assay was carried out according to the procedure adopted by the
NCI’s Developmental Therapeutics Program [8,19,20]. Briefly, cells were plated in 96-well plates
(5 ˆ 103 cells/well for MCF-7 and NCI-H460 cells; 7.5 ˆ 103 cells/well for A375-C5; 2 ˆ 103 cells/well
for HeLa cells) in the respective culture medium and incubated at 37 ˝C for 24 h. Cells were then
incubated for 48 h with 5 serial dilutions of the each compound (at a maximum of 37.5 µM for
TXA1,15 µM for TXA1¨HCl and 150 µM for all the other compounds) at 37 ˝C and 5% CO2. Cells
were with 10% (w/v) trichloroacetic acid (TCA), washed with distilled water, and proteins stained with
0.4% (w/v) SRB. After washing with 1% (v/v) acetic acid, bound SRB was solubilized with 10 mM Tris
base and absorbance measured at 510 nm. For each compound analyzed, the GI50 (the concentration
that inhibits 50% of cell growth) was determined by interpolation of the dose-response curve graphic
obtained using a NCI datasheet.
3.7. Confirmation of the Activity of the Hit Compounds (TXA1 and TXA¨HCl) with the
3-(4,5-Dimethyl-thiazolyl-2)-2,5-diphenyltetrazolium Bromide (MTT) Assay
Cells were plated in 96-well plates (2.0 ˆ 103 cells/well for A375-C5 cells, 5 ˆ 103 cells/well for
MCF-7 and NCI-H460 cells and 5ˆ 103 cells/well for HeLa cells) in the respective culture medium and
incubated at 37 ˝C for 24 h. Cells were then incubated for 48 h with TXA1 or TXA1¨HCl (concentrations
ranging from 2.3–21.1 µM) at 37 ˝C and 5% CO2. MTT, previously dissolved in PBS, was then added to
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each well (0.5 mg/mL final concentration) and incubated for 4 additional hours in the same conditions.
Formazan crystals were then solubilized by adding 100 µL solubilization solution. Absorbance values
were read at 550 nm. Dose-response curves were plotted and IC50 values were obtained using the
GraphPad Prism® version 6.0c software.
3.8. Reversibility Analysis of the Effect of the Hit Compound, with the MTT Assay and the Colony
Forming Assay
For the reversibility studies, the MTT was carried out (as described in the previous section) in
MCF-7 cells after treatment for 6, 12, 24 or 48 h with 5, 10 or 20 µM TXA1¨HCl. In addition, after each
treatment period, TXA1¨HCl was removed, cells were washed with PBS and further incubated for
additional 24 and 48 h in compound-free cell culture medium at 37 ˝C and 5% CO2. MTT assay was
also carried out at the end of these experiments.
For the colony forming assay, MCF-7 cells (7.5 ˆ 102 cells/well in 6-well plates) were plated
in cell culture medium and incubated for 24 h at 37 ˝C in 5% CO2 to allow cell adhesion. Cells
were then treated for 6 h or 24 h with 5, 10 or 20 µM TXA1¨HCl. Cells were also incubated with
medium only (Blank) or with the corresponding concentrations of H2O (Control). After treatment,
the compound-containing medium was discarded and cells further incubated with fresh cell culture
medium for 14 days. The resulting colonies were fixed with 3.7% (v/v) paraformaldehyde and stained
with 0.05% (w/v) crystal violet (in distilled water). All plates were photographed in a Gel Doc™ XR
system (Bio-Rad, Hercules, CA, USA) and colonies were manually counted.
3.9. Study of the Effect of the Hit Compound on Cell Death
MCF-7 (1 ˆ 105 cells/well) were plated in 6-well plates in cell culture medium and incubated for
24 h at 37 ˝C in 5% CO2 to allow cell adhesion. Cells were then treated for 24, 48 and 72 h with 5, 10 or
20 µM TXA1¨HCl. Cells were also incubated with medium only (Blank) or with the higher volume of
the solvent (H2O, Control).
For morphology analysis, cells were observed under phase contrast microscopy, in a Nikon
Eclipse TE2000-U microscope equipped with a DXM1200F digital camera and controlled by Nikon
ACT-1 software (Melville, NY, USA), and images were acquired with a 40ˆmagnification.
For the TUNEL assay, the DeadEnd™ Fluorometric TUNEL System (Promega, Madison, WI,
USA) was used, according to the manufacturer’s instructions. Briefly, after cytospins were prepared,
cells were fixed in 4% (v/v) paraformaldehyde in PBS, permeabilized with 0.2% (v/v) Triton X-100 in
PBS and incubated with TUNEL reaction mixture (enzyme dilution 1:20). Slides were then mounted
with Vectashield with DAPI and analyzed by fluorescence microscopy under a Zeiss Spinning Disc
AxioObserver Z.1 SD microscope, coupled to an AxioCam MR3 camera (Carl Zeiss, Jena, Germany).
The percentage of TUNEL positive labelled cells was determined by a counting at least 1000 cells for
each condition [21].
For flow cytometric analysis of apoptotic cell death, the “Annexin V-FITC Apoptosis Detection kit”
(Bender MedSystems, Vienna, Austria) was used as previously described [22]. Briefly, cell pellets were
resuspended in binding buffer and incubated with Annexin V-FITC and with propidium iodide. Cells
were then analyzed by flow cytometry in a BD Accuri C6 cytometer (BD Biosciences, Erembodegem,
Belgium). All data was analyzed using the FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA),
plotting at least 20,000 events per sample.
3.10. Statistical Analysis
All presented data were obtained from at least three independent. All data was statistically
analyzed with the two-tailed paired Student’s t-test. Results were considered statistically significant
when p ď 0.05.
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4. Conclusions
In the present study, the tumor cell growth inhibitory effect of a series of 27 thioxanthones was
analyzed in three human tumor cell lines derived from solid tumors: MCF-7 (breast adenocarcinoma),
NCI-H460 (non-small cell lung cancer) and A375-C5 (melanoma). This revealed the compound
1-{[2-(diethylamino)ethyl]amino-4-propoxy-9H-thioxanthen-9-one (TXA1) as the most potent
compound from this small library. Its hydrochloride derivative, TXA1¨HCl, was synthesized in
order to improve the solubility as well as the bioavailability of this compound. Both TXA1 and
TXA1¨HCl decreased MCF-7 tumor cell growth. The effect of TXA1¨HCl was found to be irreversible.
Additionally, the effect of this hit compound was found to be, at least in part, due to cell death by
apoptosis. Future work will allow to further elucidate its mechanisms of action.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/1/81/s1.
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